Merck Discontinues Recarbio Antibiotic Despite Superbug Resistance Concerns

Source Summary

Merck has discontinued Recarbio, an important antibiotic used in the United States, despite ongoing concerns about resistance to superbugs. The discontinuation raises questions about the availability of treatment options for resistant bacterial infections.

Why it matters

The discontinuation of an antibiotic amid superbug resistance concerns reduces treatment options for serious resistant bacterial infections.

What remains uncertain

The source does not specify Merck's stated reason for the discontinuation or the timeline of the decision.

Read the Source

• STAT News ↗